Please assess the completion status of the following clinical trial:

Trial Title: Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male sex (at birth)~* HIV uninfected~* Age having reached the local age of consent~* High risk for HIV infection including any of the following: 1) No condom use during anal intercourse with a male HIV-positive partner or a male partner of unknown HIV status during the last 6 months; (2) anal intercourse with more than 3 male sex partners during the last 6 months; (3) exchange of money, gifts, shelter, or drugs for anal sex with a male partner during the last 6 months; (4) sex with a male partner and STI diagnosis during the last 6 months or at screening, or (5) sexual partner of an HIV-infected man with whom condoms are not consistently used in the last 6 months.~* Able to provide a street address of residence for themselves and one personal contact who would know their whereabouts during the study period~* Healthy enough to work, as indicated by score of 80 or greater on the Karnofsky scale~* Certain laboratory values~* A urine dipstick with a negative or trace result for both glucose and protein within 28 days of enrollment.~* Ability to understand and local language for which an informed consent form has been approved by a local IRB and registered with the study sponsor.~Inclusion Criteria for Open-Label Extension:~* Participated in a randomized, placebo-controlled, PrEP trail~* Has been unblinded~* Has provided informed consent~Exclusion Criteria:~* Previously diagnosed active and serious infections, including tuberculosis infection, osteomyelitis, or infections requiring parenteral antibiotic therapy~* Active clinically significant medical problems including heart disease (e.g., symptoms of ischemia, congestive heart failure, arrhythmia), lung disease (steroid-dependent chronic obstructive pulmonary disease), diabetes requiring hypoglycemic medication, or previously diagnosed cancer expected to require further treatment~* Acute HBV infection at the screening visit or presence of treatment indications for hepatitis B based on local practice standards; or clinical signs of hepatic cirrhosis~* History of pathological bone fractures not related to trauma~* Receiving ongoing therapy with certain HIV/AIDS-related medications or other medications as determined by the investigator~* Definitely or possibly received an anti-HIV vaccine while participating in a blinded clinical trial~* Current alcohol or drug use that, in the opinion of the investigator, may interfere with the study~* Current participation in a clinical trial or cohort study other than sub-studies of this protocol~* Any condition at enrollment that, in the opinion of the investigator, would make participation in the study unsafe or would interfere with the study~* Sites may utilize additional criteria that restrict enrollment to a subset of people who meet the protocol-defined enrollment criteria.~Exclusion Criteria for Open-Label Extension:~- Site leadership believes participant will have difficulty completing requirements

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- TDF/FTC (Type: EXPERIMENTAL): Drug. Daily oral tablet of co-formulated 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate (TDF/FTC).
- Placebo (Type: PLACEBO_COMPARATOR): Drug. Daily oral placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).